by Cassie Arnold | Nov 10, 2020 | Biotech Finance, Deal making, Digital Health, Digital Therapeutic
Tired from a long week of parsing electoral college votes? How about focusing on digital therapeutic deals for a change of pace? The third quarter brought a record number of digital therapeutic deals with a total of 19. That’s up from 16 in the previous quarter. The...
by Cassie Arnold | Feb 25, 2020 | Biotech Finance, Digital Health, Digital Therapeutic
When I started following the digital health sector in earnest about ten years ago, I was intrigued with the potential of digital technology to treat disease – the so-called digital therapeutics. Instead, the sector produced an almost infinite variety of activity...
by Cassie Arnold | Mar 10, 2017 | Biotech Finance
Is an Ad Campaign the Solution or the Problem? Recently the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing the US pharmaceutical industry, launched an unprecedented image campaign titled “Go Boldly.” The campaign was rolled...
by Cassie Arnold | Jan 30, 2017 | Biotech Finance
2017: Above Average VC Investment, Maybe a Record for M&A I’m breaking with tradition and publishing my own predictions for the life sciences sector in 2017. I do research like this all the time for clients, but I never put it out under my own name. I’m taking...
